Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-1018 for H5N8 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A Group 1 Vaccine: mRNA-1018 for H5N8 Dose Level 1 | EXPERIMENTAL | Participants will receive mRNA-1018 for H5N8 at dose level 1 by intramuscular (IM) injection on Day 1 and Day 22. |
| Part A Group 1 Vaccine: mRNA-1018 for H5N8 Dose Level 2 | EXPERIMENTAL | Participants will receive mRNA-1018 for H5N8 at dose level 2 by IM injection on Day 1 and Day 22. |
| Part A Group 1 Vaccine: mRNA-1018 for H5N8 Dose Level 3 | EXPERIMENTAL | Participants will receive mRNA-1018 for H5N8 at dose level 3 by IM injection on Day 1 and Day 22. |
| Part A Group 1 Vaccine: mRNA-1018 for H5 Only Dose Level 1 | EXPERIMENTAL | Participants will receive mRNA-1018 for H5 only at dose level 1 by IM injection on Day 1 and Day 22. |
| Part A Group 1 Vaccine: mRNA-1018 for H5 Only Dose Level 2 | EXPERIMENTAL | Participants will receive mRNA-1018 for H5 only at dose level 2 by IM injection on Day 1 and Day 22. |
| Part A Group 1 Vaccine: mRNA-1018 for H5 Only Dose Level 3 | EXPERIMENTAL | Participants will receive mRNA-1018 for H5 only at dose level 3 by IM injection on Day 1 and Day 22. |
| Part A Group 2 Vaccine: mRNA-1018 for H7N9 Dose Level 1 | EXPERIMENTAL | Participants will receive mRNA-1018 for H7N9 at dose level 1 by IM injection on Day 1 and Day 22. |
| Part A Group 2 Vaccine: mRNA-1018 for H7N9 Dose Level 2 | EXPERIMENTAL | Participants will receive mRNA-1018 for H7N9 at dose level 2 by IM injection on Day 1 and Day 22. |
| Part A Group 2 Vaccine: mRNA-1018 for H7N9 Dose Level 3 | EXPERIMENTAL | Participants will receive mRNA-1018 for H7N9 at dose level 3 by IM injection on Day 1 and Day 22. |
| Part A Group 2 Vaccine: mRNA-1018 for H7 Only Dose Level 1 | EXPERIMENTAL | Participants will receive mRNA-1018 for H7 only at dose level 1 by IM injection on Day 1 and Day 22. |
| Part A Group 2 Vaccine: mRNA-1018 for H7 Only Dose Level 2 | EXPERIMENTAL | Participants will receive mRNA-1018 for H7 only at dose level 2 by IM injection on Day 1 and Day 22. |
| Part A Group 2 Vaccine: mRNA-1018 for H7 Only Dose Level 3 | EXPERIMENTAL | Participants will receive mRNA-1018 for H7 only at dose level 3 by IM injection on Day 1 and Day 22. |
| Part B Group 1 Vaccine: mRNA-1018 for H5 Only-CG Dose Level 1 | EXPERIMENTAL | Participants will receive mRNA-1018 for H5 Only-CG at dose level 1 by IM injection on Day 1 and Day 22. |
| Part B Group 1 Vaccine: mRNA-1018 for H5 Only-CG Dose Level 2 | EXPERIMENTAL | Participants will receive mRNA-1018 for H5 Only-CG at dose level 2 by IM injection on Day 1 and Day 22. |
| Part B Group 1 Vaccine: mRNA-1018 for H5 Only-CG Dose Level 3 | EXPERIMENTAL | Participants will receive mRNA-1018 for H5 Only-CG at dose level 3 by IM injection on Day 1 and Day 22. |
| Name | Type | Description |
|---|---|---|
| mRNA-1018 for H5N8 | BIOLOGICAL | Sterile liquid for injection |
| mRNA-1018 for H7N9 | BIOLOGICAL | Sterile liquid for injection |
| mRNA-1018 for H5 Only | BIOLOGICAL | Sterile liquid for injection |
| mRNA-1018 for H7 Only | BIOLOGICAL | Sterile liquid for injection |
| mRNA-1018 for H5 Only-CG | BIOLOGICAL | Sterile liquid for injection |
Key Inclusion Criteria: * Healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and results of electrocardiogram testing. * Body mass index of 18 kilograms (kg)/square meter (m\^2) to 39 kg/m\^2 (inclusive) at the Screening visit. * For femal...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
mRNA-1018 for H5N8 is an investigational mRNA vaccine developed by Moderna, Inc. for pandemic influenza. It is designed to protect against the H5N8 avian influenza strain and is in Phase 1 clinical development. The vaccine is being studied in healthy adults.
mRNA-1018 for H5N8 is being developed by Moderna, Inc., which trades on the Nasdaq under the ticker MRNA. Moderna is the sponsor of the clinical program evaluating this pandemic influenza vaccine candidate.
mRNA-1018 for H5N8 is in Phase 1 clinical development. The Phase 1 trial has been completed, and the vaccine remains investigational. It has not been approved by the FDA or any other regulatory agency for use in humans.
mRNA-1018 for H5N8 has been evaluated in one clinical trial: NCT05972174, titled "A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults." This Phase 1 trial enrolled 1,504 participants across the United States and the United Kingdom and is now completed.
mRNA-1018 for H5N8 is being developed for the prevention of influenza caused by the H5N8 avian influenza strain. It is a pandemic influenza vaccine candidate intended for use in healthy adults and is currently investigational.